Oncternal stock crashes by 60% as it lays off staff and scraps trials
Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
Business & Regulation
UK clinical trial sector must address prolonged timelines, say experts
Novartis plans to axe 680 employees
Intellia propels into 2024 with CRISPR pipeline updates
Pharma, patient advocates clash over Inflation Reduction Act
Joe Biden’s global corporation tax deal: A prediction on what’s next
Regulatory roundup: BMS’s T lymphocyte immunotherapy tripped by lung cancer trial termination
Regulatory roundup: Ology, MaxCyte make moves in women’s cancer with divergent approval chances
